FDA Approves Guerbet's Dotarem® (gadoterate meglumine) for Pediatric Patients Younger Than Two Years
PRINCETON, N.J., Sept. 5, 2017 /PRNewswire/ -- Guerbet LLC USA, the US affiliate of the global specialist in contrast products and solutions for medical imaging, announced today that the US Food and Drug Administration (FDA) has approved Dotarem® (gadoterate meglumine) for intravenous use with magnetic resonance imaging (MRI) in pediatric patients under two years old, including term neonates, to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS).
Dotarem was previously approved for this use in patient populations over the age of two.
This supplemental indication fulfills a post marketing requirement, acknowledged when Dotarem was first registered in March 2013, to strictly comply with the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c).
The FDA's review was based on a study showing that at the standard dose (0.1 mmol/kg),(1 )the pharmacokinetic (PK) and safety profiles in pediatric patients under two were similar to those of older children and adults.
The study enrolled 51 pediatric patients in nine centers, with ages spanning from term neonates to 23 months and with normal renal function. It evaluated 45 pediatric patients for PK profile and safety, including five subjects aged less than one month and nine subjects aged one to three months. It assessed efficacy in a subset of 28 subjects who underwent an MRI examination of brain, spine, and associated tissues.
In this pediatric population the observed safety profile of Dotarem was consistent with what has been reported in older populations. In one patient, rash was reported as a moderate adverse event. Serious AEs unrelated to Dotarem were reported in one out of 45 patients. Evaluation of images from contrast-enhanced MRI of the CNS supported extrapolation of CNS efficacy findings reported in adults and older children.
"It is critical for Guerbet to help patients and their healthcare providers meet this medical need. We are committed to providing safe and effective contrast media to improve diagnosis of all populations including those who need special care, like young children. In fact, a study published earlier this year in Pediatric Radiology found that 80% of children's hospitals surveyed now use macrocyclic contrast agents(2)," said Massimo Carrara, VP North America.
Dotarem is the only macrocyclic and ionic gadolinium-based contrast medium (a kind that provides high molecular stability) available in the US.
To date, Dotarem is approved in 79 countries worldwide. More than 65 million doses of Dotarem have been administered since first launch. No unconfounded cases of NSF have been reported for Dotarem.
Ref 1: Dotarem(®)(gadoterate meglumine) US Prescribing Information
Ref 2: Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America.Pediatr Radiol. 2017 May;47(6):657-664.
About DOTAREM(®) (gadoterate meglumine) Injection
For more information about DOTAREM, including complete Boxed Warning, please see the Full Prescribing Information.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF
among patients with impaired elimination of the drugs. Avoid use of
GBCAs in these patients unless the diagnostic information is
essential and not available with non-contrasted MRI or other
modalities. NSF may result in fatal or debilitating fibrosis
affecting the skin, muscle and internal organs.
The risk for NSF appears highest among patients with:
Chronic,
severe kidney disease (GFR < 30 mL/min/1.73m(2)), or
Acute
kidney injury.
Screen patients for acute kidney injury and other
conditions that may reduce renal function. For patients at risk for
chronically reduced renal function (e.g. age > 60 years,
hypertension, diabetes), estimate the glomerular filtration rate
(GFR) through laboratory testing.
For patients at highest risk for
NSF, do not exceed the recommended DOTAREM dose and allow a
sufficient period of time for elimination of the drug from the body
prior to any re-administration.
--------------------------------------------------------------------
Indication and Usage
DOTAREM(®) (gadoterate meglumine) injection is a prescription gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.
Contraindications
History of clinically important hypersensitivity reactions to DOTAREM.
Warnings and Precautions
-- Anaphylactic and anaphylactoid reactions have been reported with
DOTAREM, involving cardiovascular, respiratory, and/or cutaneous
manifestations. Some patients experienced circulatory collapse and died.
In most cases, initial symptoms occurred within minutes of DOTAREM
administration and resolved with prompt emergency treatment.
-- Before DOTAREM administration, assess all patients for any history of a
reaction to contrast media, bronchial asthma and/or allergic disorders.
These patients may have an increased risk for a hypersensitivity
reaction to DOTAREM.
-- Administer DOTAREM only in situations where trained personnel and
therapies are promptly available for the treatment of hypersensitivity
reactions, including personnel trained in resuscitation.
-- In patients with chronically reduced renal function, acute kidney injury
requiring dialysis has occurred with the use of GBCAs. The risk of acute
kidney injury may increase with increasing dose of the contrast agent;
administer the lowest dose necessary for adequate imaging.
-- Ensure catheter and venous patency before the injection of DOTAREM.
Extravasation into tissues during DOTAREM administration may result in
tissue irritation.
Adverse Reactions
-- The most common adverse reactions associated with DOTAREM in clinical
trials were nausea, headache, injection site pain, injection site
coldness and rash.
-- Serious adverse reactions in the Postmarketing experience have been
reported with DOTAREM. These serious adverse reactions include but are
not limited to: arrhythmia, cardiac arrest, respiratory arrest,
pharyngeal edema, laryngospasm, bronchospasm, coma and convulsion.
Use in Specific Populations
-- Pregnancy: There are no available data with DOTAREM use in pregnant
women to inform a drug-associated risk of adverse developmental
outcomes. While it is unknown if gadoterate crosses the placenta, other
GBCAs have been shown to cross the human placenta and result in fetal
exposure. Advise pregnant women of the potential risk of fetal exposure
to GBCAs.
-- Lactation: There are no data on the presence of gadoterate in human
milk, the effects on the breastfed infant, or the effects on milk
production. However, published lactation data on other GBCAs indicate
that 0.01 to 0.04% of the maternal gadolinium dose is present in breast
milk.
-- Pediatric Use: The safety and efficacy of DOTAREM at a single dose of
0.1 mmol/kg has been established in pediatric patients from birth (term
neonates >= 37 weeks gestational age) to 17 years of age based on
clinical data. The safety of DOTAREM has not been established in preterm
neonates. No cases of NSF associated with DOTAREM or any other GBCA have
been identified in pediatric patients age 6 years and younger.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.
About Guerbet
Guerbet is a pioneer in the contrast agent field with over 90 years' of experience and is one of the leaders in medical imaging worldwide. It offers a full range of pharmaceutical products, medical devices and services for X-ray (RX) and Magnetic Resonance Imaging (MRI) scanners and Interventional Radiology and Theranostics (IRT) to improve the diagnosis and treatment of patients. With 7% of its revenue and more than 200 employees dedicated to R&D, Guerbet invests heavily in research and innovation. Guerbet (GBT) is listed on Euronext Paris (Segment B - Mid Caps) and generated EUR776 million in revenue in 2016. For more information about Guerbet, visit www.guerbet.com
View original content:http://www.prnewswire.com/news-releases/fda-approves-guerbets-dotarem-gadoterate-meglumine-for-pediatric-patients-younger-than-two-years-300513996.html
SOURCE Guerbet LLC USA
